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ECONOMIC EVALUATION OF A SAFETY DEVICE 
FOR SUBCUTANEOUS INJECTIONS OF LOW 
MOLECULAR WEIGHT HEPARIN (LMWH)
Durand-Zaleski I1, Gabriel S2, Dinet J2
1Hôpital Henri-Mondor, Creteil, France; 2Health Economics 
Department, Sanofi-Synthelabo, Bagneux, France
Subcutaneous injections account for an increasing share
of total needle-stick injuries (NSI). OBJECTIVE: The ob-
jective was to document the possible cost savings related
to the introduction of a protected needle (safety shaft)
used to administer LMWH. METHODS: We estimated
the frequency and the costs of NSI attributable to treat-
ment with LMWH in a tertiary care hospital, and mod-
eled a countrywide estimate. Risks: We collected data on
yearly NSI due to recapping in a large tertiary care center
and related this figure to the total number of needles
used. We derived a risk of NSI per 100,000 needles used
and multiplied it by the number of injections with
LMWH per year in hospitals countrywide. Costs: we esti-
mated the cost of a NSI from the resources used in the
hospital to manage personnel after a NSI. The actual re-
sources used were prospectively collected during the year
1997 and were compared to other observed data (hospi-
tal survey). From these data we built a decision tree and
compared the results to the recommended practice. Costs
were estimated from the viewpoints of both hospital and
society. Infection: the costs related to the risk of viral in-
fection were not included. RESULTS: The rate of NSI
due to recapping was 5.2 per 100,000 punctures, the to-
tal number of LMWH needles used in hospitals was
14,861,000. The total societal cost of managing a NSI
was assessed to be $1919 assuming that all the recom-
mended procedures were followed. From the hospital
viewpoint, the cost became $1174. The large discrepancy
between recommended and actual practice lead to signifi-
cant reductions in costs. The potential savings linked to
the use of the safety device were conservatively estimated.
CONCLUSION: Using safer devices for LMWH injec-
tions may result in cost savings by reducing the costs of
NSI management.
PHV7
MANAGING PNEUMOCYSTOSIS: THE COST OF 
HOSPITALIZATION IN THE US
O’Brien J, Pierce D, Caro J
Caro Research, Concord, MA, USA
Highly active antiretroviral therapy (HAART) has made
it possible to retard progression from the HIV positive
state to AIDS. Today’s health care decision-makers re-
quire the examination of the economic, as well as the
clinical consequences of emerging therapies. To under-
stand the full economic impact of HAART, it is necessary
to examine the cost consequences of transitioning from
HIV to AIDS. The occurrence of opportunistic infections
hallmarks this transition. OBJECTIVES: To determine
the hospitalization costs of pneumocystosis (pneumonia
due to Pneumocystis carinii), one of the more prevalent
opportunistic infections associated with AIDS. METH-
ODS: Cost estimates for inpatient care were developed
using data from 5 all payer, state 1996/97 discharge da-
tabases (CA, FL, MA, MD, WA). A strict hierarchical
methodology using ICD9 codes was used to identify
AIDS cases admitted primarily for treatment of pneu-
mocystosis. Disposition status was used to identify those
who died during hospitalization and post-discharge care.
Hospital costs include all accommodation and ancillary
services. Physician costs are not included. Costs are re-
ported in 1999 US $, adjusted appropriately for medical
inflation and cost-to-charge ratios. RESULTS: Of the
48,782 AIDS-related discharges identified, 1633 (3.3%)
were documented to be admitted primarily due to pneu-
mocystosis. During hospitalization, 9% of this group
died. The mean cost of hospitalization for those who died
($31,370) was three times greater than the average cost
for those who survived ($10,420). CONCLUSIONS:
Pneumocystosis represents a costly manifestation of
AIDS and highlights the cost consequences of AIDS man-
agement. Thus, understanding the difference in manage-
ment costs of HIV and AIDS is an integral component of
an economic analysis of new HAART regimens.
PHV8
UNCOMPLICATED ACUTE PYELONEPHRITIS IN 
ADULT WOMEN: INPATIENT VERSUS 
OUTPATIENT THERAPY – 
ECONOMIC COMPARISON
Tibi-Lévy Y1, Elkharrat D2, de Pouvourville G1
1Groupe-IMAGE, ENSP, Saint-Maurice, France; 2 SAU, 
Lariboisière Hospital, Paris, France
The traditional treatment of Uncomplicated Acute Pyelo-
nephritis (UAP) is hospitalization and parenteral antibio-
therapy. Some authors suggest that administration of
oral antibiotics is as efficient as a traditional treatment
and allows ambulatory therapy. OBJECTIVES: The
study purpose was to compare, with identical demon-
strated effectiveness, the resources mobilized according
to two ways of managing women with UAP: inpatient
versus outpatient therapy. METHODS: We achieved a
multicentric (16 French emergency wards) and random-
ized cost-minimization analysis. Direct (fixed and vari-
able costs) and indirect (home help, transport charges,
stoppage) costs were calculated prospectively on 252 in-
patients and 250 outpatients. Several scenarii about the
avoided hospitalizations rate were studied (prefered sce-
nario: reduction of 50%, 15,000 annual hospitaliza-
tions). RESULTS: Ambulatory treatment reduces by
63% the direct medical costs (US$ 466 vs US$ 1278, P 
0.001) and of 2.3 days, the sick-leaves. The gain concerns
fixed costs, but also variable costs such as investigations.
The hypothesis of a transfer of expenditures to patients
was not demonstrated (US$ 29.6 vs US$ 26.5, P 
0.458). If the quality of care is similar (8.8/10 in each
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group), women prefer a posteriori an outpatient therapy
(88.6% in the group outpatient, 53.8% in the other
group), particularly because it is more restful (P 
0.001). CONCLUSION: If women prefer a posteriori an
outpatient therapy, this mode of care decreases the
amount of mobilized medical and social resources.
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COST OF TREATING HISPANIC PATIENTS 
WITH AIDS IN US HOSPITALS
O’Brien J, Pierce D, Jackson-Kelley H, Caro J
Caro Research, Concord, MA, USA
Hispanics have been reported to have one of the highest
rates of AIDS in the United States. OBJECTIVE: To ex-
amine the hospital costs and disposition status of Hispan-
ics with AIDS. METHODS: Inpatient cost estimates, ad-
justed for medical inflation and cost-to-charge ratios,
were developed using data from all-payer 1996 discharge
databases from California, Florida and Massachusetts,
supplemented with fee schedules. Log transformation
was used to address highly skewed distributions. Adults
(age 17 years) were dichotomized into Hispanic/non-
Hispanic groups. A hierarchical methodology using ICD9
and ID codes was developed to identify patient-level
data. Length-of-stay (LOS), disposition, emergency room
(ER), special care unit (SCU) and admission rates for
AIDS data were also examined. Hospital costs (i.e., ac-
commodation, ancillary, physician) are reported in 1998
US$. RESULTS: Of the 39,110 AIDS discharges, 6649
(17%) were coded as Hispanic. On average, Hispanics
were admitted for AIDS-related care 1.7 times during the
year versus 1.8 times for non-Hispanics. A difference of
0.4 days in LOS was noted between groups (Hispanics 
8.5; non-Hispanic  8.1); however, a higher mean per
diem cost of $1874 (difference  $117) was noted in the
non-Hispanic group. Thus, the difference in the overall
mean cost of a hospital stay, albeit slightly higher for
Hispanics ($14,101 vs $14,012), was small. Admission
via ER was 55% in Hispanics; 54% in non-Hispanics. Of
the 10.4% Hispanics and 9.1% non-Hispanics in SCUs,
SCU time accounted for 50% and 52% of the stay in each
group, respectively. Of those discharged alive, 2.6% more
of the non-Hispanics were referred for formal health care
services. CONCLUSIONS: Although some differences ex-
ist, the results do not appear to constitute a substantial
differential economic consequence between the groups.
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A PRELIMINARY STUDY: THE 
PHARMACOECONOMIC PROFILE OF 
ANTIBIOTIC USE IN TURKEY
Sapci H1, Bozkurt E2, Durlu T2, Kandilci B2, Ozsogut B2, 
Demirdamar R2
1Numune Hospital, Ankara, Turkey; 2Faculty of Pharmacy, 
Hacettepe University, Ankara, Turkey
There are few analyses on rational drug prescription in
Turkey. The main social security systems which are
Emekli Sandigi and Bag-Kur have to reimburse and the
cost is very high. Due to the reimbursement of these irra-
tional prescriptions the social security systems (Emekli
Sandigi, Bag-Kur, Sosyal Sigortalar) have reached the
point of financial crisis and the systems need reorganiz-
ing. OBJECTIVE: Our aim was to conduct a preliminary
study to be able to establish the effects of prescribing
habits on the profile of antibiotic use for the treatment of
respiratory diseases in outpatients and its economic out-
come. METHODS: For this purpose 2278 randomized
prescriptions from January 1998 to September 1999
were collected from Emekli Sandigi and Bag-Kur. The
medical information including the length of time the
medications were extracted. RESULTS: The analysis on
the antibiotics prescribed revealed that of the total 6824
medicines 572 were antibiotics (8.4%). While sulbactam-
ampicillin was the widely prescribed antibiotic (20%),
azithromycin was the least (3%). The average total cost
of antibiotic treatment was $10.46 (range $1.27–$26.56)
per patient. CONCLUSIONS: Taking the results of this
pilot study into consideration, a master study for Turkey
is planned which will include cost-effectiveness analyses
for the empiric management of polymicrobial infections.
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COST-MINIMIZATION ANALYSIS OF 
AZITHROMYCIN IV/PO VERSUS CEFUROXIME 
IV/PO  ERYTHROMYCIN IV/PO FOR 
COMMUNITY-ACQUIRED PNEUMONIA
Wong AH1,2, Phillips E2, Tailor SAN2, Cornish W2, Shear 
NH1,2, Lavoie F3
1HOPE Research Centre, Toronto, ON, Canada; 2Sunnybrook 
and Women’s College Health Sciences Centre, Toronto, ON, 
Canada; 3Pfizer Canada Inc., Kirkland, QC, Canada
Azithromycin IV was recently approved in Canada for
the treatment of community-acquired pneumonia (CAP)
requiring initial hospitalization. According to current
guidelines, a second or third generation cephalosporin 
a macrolide or an extended-spectrum fluoroquinolone is
preferred for first-line therapy. Azithromycin is well tol-
erated, reducing the potential for costly adverse events
and has a once daily dosing frequency, minimizing drug
preparation and administration costs. OBJECTIVES: To
compare the costs and outcomes of a 10-day course of
azithromycin IV/PO versus cefuroxime IV/PO  erythro-
mycin IV/PO. METHODS: The analysis was conducted
from the hospital perspective and considered 2 days of
intravenous followed by 8 days of oral therapy for a 10-
day course. A cost-minimization approach was used since
clinical trial results suggest similar efficacy and tolerabil-
ity between the comparators. The weighted cost of ce-
furoxime  erythromycin therapy was based on a clinical
trial where 52% of patients received cefuroxime alone
and 48% of patients received cefuroxime  erythromy-
cin for suspected atypical pathogens. The analysis in-
